From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Juvenile Diabetes Research Foundation (logo).png
Founded May 28, 1970; 48 years ago (1970-05-28)[1]
Founder Lee Ducat, Carol Lurie
Legal status 501(c)(3) nonprofit organization[3]
  • New York, NY,
Method Research funding,
Political advocacy,
Subsidiaries JDRF Theraputics Fund LLC[2]
Revenue (2016)
Expenses (2016) $189,479,405[2]
Endowment $7,176,427[2]
Employees (2015)
Volunteers (2015)
Website jdrf.org
Formerly called
Juvenile Diabetes Research Foundation

JDRF is a nonprofit 501(c)(3) organization that funds type 1 diabetes (T1D) research and advocates for regulation favorable to medical research and that makes it easier to market new medical devices. It was formerly called the Juvenile Diabetes Research Foundation.


JDRF generally funds research directed to finding a cure for juvenile diabetes; in the 2000s it broadened its research efforts to include ways to better manage the disease and ways to prevent it.[4]

In 2005 the board of JDRF committed to supporting work on medical devices to manage blood glucose, known as "artificial pancreas technology. The Board was urged to do so by Jeffrey Brewer, who had founded and sold Citysearch and had become intensely interested in juvenile diabetes and medical devices after his son was diagnosed with the condition.[5]

The project brought together academic researchers and medical device companies. The focus was on integrating continuous glucose monitors (CGM's) and insulin pumps via a computerized program that would use blood glucose levels obtained through the CGM to calculate an insulin dosage to be dispensed through the insulin pump.[6][7] The first such device was approved in 2016.[8]


In 2011 the FDA had made it a priority to clarify the requirements for approval for such a closed-loop monitoring and drug delivery device for TID, and in 2011 announced it was preparing draft guidelines. JDRF launched a campaign to influence those guidelines to be lenient.[6] After the first closed loop device was approved in 2016, JDRF lobbied insurance companies to cover it.[9] It also put resources into educating people with diabetes on how to navigate health insurance in the United States, and into lobbying Congress to continue funding diabetes research through the NIH.[9]

JDRF has advocated for stem cell research; in a 2004 article in The Wall Street Journal, the authors observed that the JDRF "... has become adept at unleashing an army of hard-to-resist lobbyists -- made up of determined parents and their afflicted children -- on researchers, politicians and potential donors."[10]

Kick-It for JDRF is an annual charity soccer tournament in Springfield, PA. It has raised several thousand dollars in its 5 years of existence.

See also[edit]


  1. ^ "JDRF International". Pennsylvania Department of State. Retrieved September 27, 2017.
  2. ^ a b c d e f g "Form 990: Return of Organization Exempt from Income Tax". JDRF International. Guidestar. June 30, 2016.
  3. ^ "JDRF". Exempt Organizations Select Check. Internal Revenue Service. Retrieved September 27, 2017.
  4. ^ Insel, RA; Deecher, DC; Brewer, J (January 2012). "Juvenile Diabetes Research Foundation: mission, strategy, and priorities". Diabetes. 61 (1): 30–5. doi:10.2337/db11-1398. PMC 3237656. PMID 22187372.
  5. ^ "Robotic Pancreas: One Man's Quest to Put Millions of Diabetics on Autopilot". Wired Magazine, April 19, 2010. Retrieved 10 May 2013.
  6. ^ a b Dolgin, E (17 May 2012). "Medical devices: Managed by machine" (PDF). Nature. 485 (7398): S6–8. PMID 22616096.
  7. ^ "Artificial Pancreas Gives Girl a Vacation from Diabetes". CNN, March 4, 2012. Retrieved 10 May 2013.
  8. ^ Robbins, Rebecca (3 October 2016). "The risky bet behind the first 'artificial pancreas' for diabetes". STAT.
  9. ^ a b Hoskins, Mike (December 7, 2017). "JDRF Gets Aggressive on Better Diabetes Insurance Coverage". Healthline.
  10. ^ Regalado, A; Waldholz, M (31 March 2004). "Ballot drive puts stem-cell funding in voters' hands. In California, diabetes groups show growing influence as they push for research; big backing from Hollywood". Wall Street journal (Eastern ed.): A1, A12. PMID 15250089.

External links[edit]